Qinghai Provincial Key Laboratory of Tibetan Medicine Pharmacology and Safety Evaluation, Northwest Institute of Plateau Biology, Chinese Academy of Science, Xining, China; State Key Laboratory of Tibetan New Drug Development, Institute of Tibetan Medicine of Qinghai Province, Xining, China.
Department of Orthopaedics, People's Hospital of Qinghai Province, Xining, China.
Ann Palliat Med. 2020 Sep;9(5):3249-3260. doi: 10.21037/apm-20-1492. Epub 2020 Sep 14.
Ma-Nuo-Xi decoction (MNXD), as well as its hundreds of derivative preparations, has been used in Tibetan medicine since the 14th century. MNXD is in accordance with the theory of treatment determination based on syndrome differentiation. This study aimed to compare the effect of the auxiliary MNXD prescription (MNXD-AD) with that of the basic MNXD prescription (MNXD-BD) on the immunostimulating activity of MNXD.
The immunopotentiation of MNXD, MNXD-BD, and MNXD-AD was evaluated using a cyclophosphamide (CTX)-immunosuppressed mouse model. Their influences on non-specific and specific immunity were evaluated using immune organ indexes, peripheral white blood cell (WBC) count, red blood cell (RBC) count, platelet count, phagocytosis, macrophage-secreted nitric oxide (NO) and cytokines, natural killer (NK) cytotoxic activity, lymphocyte proliferation, serum cytokines, splenic T-lymphocyte subpopulations, and quantitative hemolysis of sheep red blood cell (QHS SRBC) assays.
MNXD, MNXD-BD, and MNXD-AD increased the spleen and thymus indexes, as well as the peripheral WBC, RBC, and platelet counts. They also promoted phagocytosis, NO and cytokine secretion from macrophages, NK cytotoxic activity, and lymphocyte proliferation, and also raised the CD4+ /CD8+ T-cell ratio, serum cytokine concentrations, and haemolysin formation in CTX-treated immunosuppressed mice. Compared with MNXD-BD and MNXD-AD, MNXD was superior in restoring the phagocytic index, concanavalin A (ConA)-induced T-lymphocyte proliferation, NO secretion from macrophages, and haemolysin formation, as well as the levels of interleukin 1 beta (IL-1β), and serum interleukin-2 (IL-2) and interferon gamma (INF-γ).
MNXD, MNXD-BD, and MNXD-AD have excellent immunostimulating and myelosuppression-restoring activities on CTX-immunosuppressed mice. Among them, MNXD-AD might be an immunomodulator, which may happen to be in line with the clinical experience of Tibetan medicine physicians of using it to promote the efficacy of MNXD-BD.
麻诺西（Ma-Nuo-Xi）汤，以及它的数百种衍生制剂，自 14 世纪以来一直被藏医使用。麻诺西汤是根据基于证候辨别的治疗原则制定的。本研究旨在比较辅助麻诺西汤处方（MNXD-AD）与基本麻诺西汤处方（MNXD-BD）对麻诺西汤免疫刺激活性的影响。
使用环磷酰胺（CTX）免疫抑制小鼠模型评价麻诺西汤、MNXD-BD 和 MNXD-AD 的免疫增强作用。通过免疫器官指数、外周血白细胞（WBC）计数、红细胞（RBC）计数、血小板计数、吞噬作用、巨噬细胞分泌的一氧化氮（NO）和细胞因子、自然杀伤（NK）细胞细胞毒性、淋巴细胞增殖、血清细胞因子、脾 T 淋巴细胞亚群和绵羊红细胞（QHS SRBC）定量溶血试验评估它们对非特异性和特异性免疫的影响。
麻诺西汤、MNXD-BD 和 MNXD-AD 增加了脾和胸腺指数以及外周血 WBC、RBC 和血小板计数。它们还促进了吞噬作用、NO 和细胞因子从巨噬细胞分泌、NK 细胞细胞毒性和淋巴细胞增殖，并提高了 CTX 处理的免疫抑制小鼠中的 CD4+ / CD8+ T 细胞比值、血清细胞因子浓度和溶血素形成。与 MNXD-BD 和 MNXD-AD 相比，麻诺西汤在恢复吞噬指数、刀豆蛋白 A（ConA）诱导的 T 淋巴细胞增殖、巨噬细胞 NO 分泌和溶血素形成方面，以及白细胞介素 1β（IL-1β）、血清白细胞介素 2（IL-2）和干扰素 γ（INF-γ）水平方面更具优势。
麻诺西汤、MNXD-BD 和 MNXD-AD 对 CTX 免疫抑制小鼠具有良好的免疫刺激和骨髓抑制恢复作用。其中，MNXD-AD 可能是一种免疫调节剂，这可能符合藏医医生使用它来增强 MNXD-BD 疗效的临床经验。
